Member Info for Bella6532

Https://avacta.com/wp-content/uploads/2023/06/FY22-ARA-Final-Print-Version.pdf

Geez...you could have worked out the companies cash position yourselves by reading the accounts. Don't blame others for what they choose to do with their shares.

And for those worried about share options...again read the accounts...AS let one lot lapse and has a bunch which are exciserable (and so does EF and TG) but have chosen not to.

Unlike some on here, there are not in it to make a quick buck...

BV...'Do you want to bet on that?' No, because I did not define what the clear update might be about so you will only try and wriggle out of the bet if the update does not contain what you want it to...Ha ha....!!!

Notrex...fundraising never goes down well with PIs sotting on a big paper loss. When you get large fundraisers bring large amounts of new shares to the market the SP will always suffer. I'm sure the company has been inundated with EMails re comms etc. Once the company gets out from under any comms restrictions they may be under, I'm sure we will get a very clear update.

Right now it's not worth bursting any more blood vessels unless you're here to further try and disrupt this BB which I'm sure you're not...are you? 🫣

'the bi-weekly trial (ie., a shorter dosing regimen) was always part of the plan.'...was it?...

I guess it all depends at what plan point you start from, but I don't think it was part of the original plan...

Discussions with FDA regarding the design and initiation of both the trial intended to support

331 accelerated approval and the postmarketing trial are recommended to provide evidence of

332 clinical benefit in an expeditious manner.,

So was the 2w introduced to obtain accelerated approval and the fundraise is becsuse they know they will need a postmarketing trial now too...and all points to reason for uptick in speed...all makes sense to me...

The last Poster Presentation was RNS'd/posted on Avacta website the day after (Mon) the Presentation (Sun). My guess is Monday for this one too based on time difference with US.

I think you'll find the lack of news is simply to prevent such news influencing the upcoming vote one way or another.

Is this why we now have the 2w trial...? or am I reading it incorrectly...

However,

'328 when a single-arm trial supports the accelerated approval, and FDA requires a postmarketing

329 trial to evaluate PFS or OS, a separate randomized controlled trial may be needed. Early

330 discussions with FDA regarding the design and initiation of both the trial intended to support

331 accelerated approval and the postmarketing trial are recommended to provide evidence of

332 clinical benefit in an expeditious manner.,

Insiders can only trade once info given to them as a result of them going inside is made public. Geez...it's nothing new...

I don't know serious investor be it PI or II who hasn't called it wrong sometimes...especially with AIM...early stage HIGH risk companies in the main...

Companies go t..s up for many reasons...it's part of what investing is all about...

'Avacta have given clear news milestones in the Placing RNS.'

JUNE....being the main one...3w and 2w data readout...

My husband had cancer...all clear for now...🤞🤞

He had two lots of chemo...a year apart...when his oncologist said he should start chemo, it didn't start the next day...in both cases there was a delay of a few weeks. So I think it's plausible that people have only just now been lined up for the trial and dosing started about now.

Sorry should read ...all ready to go pending funding...

B2HS2L...Read out of two-weekly and three-weekly dose escalation study data in late Q2 2024"...still good if they were all ready to pending funding...late June...3.5 months for a short 2w study is doable...question is will they still tell us when first 3 dosed

Oh dear F3rdinand...should you really be here, let alone invested!!!

'Avacta is pleased to announce that it will, subject to shareholder approval at the General Meeting to be convened at 11.00 a.m. on 18 March 2024, issue 10,896,948 Ordinary Shares at a price of 50 pence per Ordinary Share in connection with the REX Offer.'

Nov 2023 Kevin Johnson welcomed Eliot Forster as CEO to Levicept

'Kevin Johnson, Chairman of Levicept and Partner at investor Medicxi said, “….I am delighted to welcome Eliot to the company at an important time for the company,…”

Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures.

Kevin Johnson is also Chairman of Crescendo Biologics

https://www.medicxi.com/team/kevin-johnson

Crescendo are looking for partners

https://www.crescendobiologics.com/partnering-overview/

and they have two poster presentations at AACR

https://www.crescendobiologics.com/wp-content/uploads/2024/03/240306-AACR-Curtain-Raiser-PR-FINAL-1.pdf

They are also funded by Takeda.

Now would AVA028/032 be of interest to Crescendo...? is this the next pipeline product the funds are for...

https://avacta.com/therapeutics/pipeline/

Connections...Eliot Forster - Avacta & Levicept/Kevin Johnson - Medicxi, Levicept & Crescendo /European specialist healthcare fund (Medicxi ?)/Crescendo - T Cell Immunotherapy/AVA028/032 - 'enhancing T cell activation but avoiding T cell exhaustion'/Fundraiser RNS - 'progressing the current pre|CISIONTM and Affimer® pre-clinical pipelines.'

Hey ho..rock on Monday/Tuesday...

Cj62...drop them a note and ask them if they wouldn't mind making it clearer...I'm sure your note will be one of many...Ha Ha..

I think we are all getting confused because the 2w has changed the trial format...

Yes it was 1a then 1b then 2 etc

But now due to 2w being introduced...if all goes well they will look to decide their dosing from data produced from 3w and 2w. Depending on the outcomes...safety, tolerability and possibly more efficacy data. Although efficacy is not what the safety 3w and 2w trials are designed for, if good efficacy is seen in 2w they may have been given the go ahead by the FCA to forego 1b (which 2w could be seen to replace) and move straight to 2 starting which will start with dosing expansion and last for just 18 months. Again another reason why they appear to have moved up a notch and are fundraising now the change in trial sequence and the outcome of discussions with the FCA which kinda makes sense to me.

Monday/Tuesday should give us more insight into all of this.

BV...sorry I didn't exprss myself very well...when I said '1a/b (2w) is an inserted trial'...I meant 2w is being inserted between 1a and 1b...you are right they are not the same thing...